HROWNasdaqPharmaceutical PreparationsFiscal year ends December 31

HARROW, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026

$27.68+0.40 (+1.47%)

Close on Oct 19, 2026

Market cap: $1.03B
P/E (TTM): –
Dividend yield: –

HARROW, INC. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31	FY 2008 2008-12-31	FY 2007 2007-12-31	FY 2006 2006-12-31
Revenue	272	200	130	89	72	49	51	41	27	20	9.72	1.66	0.01	–	–	–	–	–	–	–
Cost of Revenue	68	49	40	25	18	14	17	17	14	–	–	–	–	–	–	–	–	–	–	–
Gross Profit	204	150	91	63	54	34	34	25	13	10	4.51	0.57	0.01	–	–	–	–	–	–	–
Research & Development	21	12	6.65	3.05	11	2.41	2.08	0.83	0.41	0.74	0.33	0.24	1.62	1.30	0.11	0.19	–	–	–	–
Selling, General & Admin	153	129	83	58	41	31	33	29	25	25	19	10	6.08	2.98	0.83	2.31	–	–	–	–
Selling & Marketing	–	–	–	–	–	–	–	–	7.06	7.38	6.50	2.39	0.09	–	–	–	–	–	–	–
General & Administrative	–	–	–	–	–	–	–	–	18	18	13	8.09	5.99	–	–	–	–	–	–	–
Advertising Expenses	8.08	6.31	3.69	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Operating Expenses	174	142	90	61	53	34	39	30	25	–	–	–	–	–	–	–	–	–	–	–
Operating Income	31	8.82	0.43	1.92	1.61	0.39	-4.80	-5.22	-12	-16	-15	-10	-7.69	-4.18	-0.94	-2.50	–	–	–	–
Interest Expense	24	23	21	7.24	5.44	–	–	–	–	–	–	0.00	–	0.01	0.08	0.06	–	–	–	–
Interest & Investment Income	–	–	–	–	–	–	–	–	–	–	–	0.03	0.04	0.02	0	0.00	–	–	–	–
Other Non-Operating Income	-32	-26	-24	-16	-19	-3.80	4.68	20	-0.76	-3.32	-1.08	0.03	0.04	–	–	–	–	–	–	–
Asset Impairment Charges	0	0.25	0.38	0	0	0	1.90	–	–	0.30	–	0	0	–	–	–	–	–	–	–
Gain (Loss) on Investments	–	-3.17	3.09	-2.91	-10	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Gain (Loss) on Sale of Assets	-0.01	–	-0.17	0.07	0.04	0.04	-0.11	-0.39	-0.35	–	–	–	–	–	–	–	–	–	–	–
Legal Settlements	–	–	–	–	–	–	–	–	-0.45	0.55	–	–	–	0	0	0	–	–	–	–
Pretax Income	-1.37	-17	-24	-14	-18	-3.42	-0.12	15	-13	-19	–	–	–	–	–	–	–	–	–	–
Income Tax Expense	3.77	0.16	0.70	0.08	0.13	0.00	0.01	–	-0.94	-0.11	0.01	0.00	–	0.00	0	–	–	–	–	–
Net Income incl. Noncontrolling Interests	–	–	–	–	-18	-3.42	-0.13	15	–	–	–	–	–	–	–	–	–	–	–	–
Minority Interest in Earnings	–	–	–	–	–	-0.06	-0.29	–	–	–	–	–	–	–	–	–	–	–	–	–
Net Income	-5.14	-17	-24	-14	-18	-3.36	0.17	15	-12	-19	-16	-10	-7.64	-5.38	-0.95	-2.53	-4.55	-3.30	-4.28	-0.58
Preferred Dividends	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0.10	–	–	–	–	–
Net Income to Common	–	-17	-24	-14	-18	-3.36	–	–	–	–	–	-10	-7.64	-5.58	-1.05	-2.53	–	–	–	–
EPS (Basic)(per share)	-0.14	-0.49	-0.75	-0.51	-0.69	-0.13	0.01	0.67	-0.60	-1.50	-1.66	-1.11	-0.88	-1.24	-2.65	-0.80	–	–	–	–
EPS (Diluted)(per share)	-0.14	-0.49	-0.75	-0.51	-0.69	-0.13	0.01	0.61	-0.60	-1.50	-1.66	-1.11	-0.88	-1.24	-2.65	-0.80	–	–	–	–
Shares Outstanding (Basic, Weighted)(shares)	37	36	33	27	27	26	25	22	20	13	9.58	9.13	8.66	4.49	0.40	–	–	–	–	–
Shares Outstanding (Diluted, Weighted)(shares)	37	36	33	27	27	26	26	24	20	13	9.58	9.13	8.66	4.49	0.40	–	–	–	–	–
EBITDA	32	10	1.49	3.17	3.19	2.09	-2.86	-3.61	-11	-15	-15	-10	–	–	–	–	–	–	–	–
Net Interest Income	–	–	–	–	-5.44	-2.24	-2.50	-2.73	-3.03	-2.77	-1.11	0.03	–	–	–	–	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 73.3%
Operating margin: -1.0%
Net margin: -13.5%
Return on equity, FY2025: -8.4%

Financial strength

Current ratio: 2.24
Debt to equity: 19.24
Debt to assets: 70.1%
Cash to current liabilities: 82.1%

Valuation

P/E ratio: –
Price to sales: 3.75
Price to book: 68.02
Dividend yield: –